Monash University and Seaport Therapeutics have developed a new approach to delivering drug molecules that piggybacks onto ...

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, ...

Non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) continue to pose significant clinical and health-economic challenges in ...

The trial will compare the safety and efficacy of equecabtagene autoleucel versus standard therapies in r/r MM patients.

Regulatory review timelines shifted from March 29 to June 29, 2026, after FDA requested more time to assess CMC/manufacturing ...

Understand the signs of premature ovarian failure and POI. Learn how to manage symptoms and protect your long-term health.

Androgenetic alopecia (AGA) is the most common form of hair loss, affecting 23–87% of the global population. It is driven by genetic predisposition ...

The post HYD Pioneers New Research Revealing Systemic Role of Deuterium-Depleted Water in Cancer Therapy appeared first on ...

GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMDCTx001 is an investigational ...

CanVeer Biopharma Inc. (the “Company” or “CanVeer”), a biopharma company advancing innovative therapeutics for severe neonatal conditions, is pleased to announce that it has received approval from ...

Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a fully funded investigator-sponsored clinical study—an ...

Clinical Product Release Testing Completed in Support of Pivotal Phase 3 Trial ATLANTA, GA - March 25, 2026 (NEWMEDIAWIRE) - ...